

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/585,562	ATTY. DOCKET NO.: Y0087.70013US01
				FILING DATE: March 6, 2007	CONFIRMATION NO.: 4715
				APPLICANT: George et al.	
				GROUP ART UNIT: 1617	EXAMINER: Jean-Louis, Samira JM

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A8	5,039,801		Brossi, et al.	08-13-1991
	A9	5,686,448		Baldone	11-11-1997
	A10	5,986,142		Magni, et al.	11-16-1999
	A11	6,121,289		Houdi	09-19-2000

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/S.J./	C23	BALLIVET et al., Nicotinic acetylcholine receptors in the nematode <i>Caenorhabditis elegans</i> . J Mol Biol. 1996 May 3;258(2):261-9.	
/S.J./	C24	BANERJEE et al., [3H]mecamylamine binding to rat brain membranes. Studies with mecamylamine and nicotine analogues. Biochem Pharmacol. 1990 Nov 1;40(9):2105-10.	
/S.J./	C25	BIANCHI et al., Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs. Pharmacology. 1973;10(4):226-37.	
/S.J./	C26	GARDINER, Genetic basis of the human epilepsies. Epilepsy Res. 1999 Sep;36(2-3):91-5.	
/S.J./	C27	EMERICH et al., Nicotine potentiates the behavioral effects of haloperidol. Psychopharmacol Bull. 1991;27(3):385-90.	
/S.J./	C28	EMERICH et al., Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. Pharmacol Biochem Behav. 1991 Apr;38(4):875-80.	
/S.J./	C29	HSU, Toxicity and Drug Interactions of Levamisole. J Am Vet Med Assoc. 1980 May 15;176(10 Spec No):1166-9.	
/S.J./	C30	STONE et al., Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives. J Med Pharm Chem. 1962 Jul;91:665-90.	
/S.J./	C31	HENNINGS et al., Nicotinic Acetylcholine Receptor Antagonistic Activity of Monoamine Uptake Blockers in Rat Hippocampal Slices. J Neurochem. 1999 Sep;73(3):1043-50.	
/S.J./	C32	MARTIN et al., Pharmacological Evaluation of the Antagonism of Nicotine's Central Effects by Mecamylamine and Pempidine. J Pharmacol Exp Ther. 1990 Jul;254(1):45-51.	

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/585,562		ATTY. DOCKET NO.: Y0087.70013us01	
				FILING DATE: March 6, 2007		CONFIRMATION NO.: 4715	
				APPLICANT: George et al.			
				GROUP ART UNIT: 1617		EXAMINER: Jean-Louis, Samira JM	
Sheet	2	of	2				

/S.J./	C33	TATTERSALL et al., Enantiospecific inhibition of emesis induced by nicotine in the house musk shrew ( <i>Suncus murinus</i> ) by the neurokinin1 (NK1) receptor antagonist CP-99,994. <i>Neuropharmacology</i> . 1995 Dec;34(12):1697-9.	
/S.J./	C34	GOODMAN et al., Depressive symptoms and cigarette smoking among teens. <i>Pediatrics</i> . 2000 Oct;106(4):748-55.	
/S.J./	C35	SANDBERG et al., Nicotine for the treatment of Tourette's syndrome. <i>Pharmacol Ther</i> . 1997;74(1):21-5.	
/S.J./	C34	DRISCOLL, Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats. <i>Psychopharmacologia</i> . 1976;46(1):119-21.	
/S.J./	C34	RUPNIAK et al., Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. <i>Br J Pharmacol</i> . 1994 Dec;113(4):1487-93.	
/S.J./	C38	SANDBERG et al., Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. <i>Biomed Pharmacother</i> . 1989;43(1):19-23.	
/S.J./	C39	SANDBERG et al., Nicotine as a Therapeutic Adjunct for Tourette's Syndrome. 1997:35-41.	
/S.J./	C40	SCHÖNENBERGER et al., Preparation of Optically Active Secondary Amines by Thermal Decomposition of (Methylbenzyl)urea Analogs: Absolute Configuration of (+)- and (-)-Mecamylamine. Preliminary Communication. <i>Helvetica Chimica Acta</i> . 1986 Oct; 69(2):283-87.	
/S.J./	C41	SUEMARU et al., Characteristics of tail-tremor induced by nicotine in rats. <i>Naunyn Schmiedeberg's Arch Pharmacol</i> . 1994 Aug;350(2):153-7.	
/S.J./	C42	SHIEH et al., Sexual Differences in the Diurnal Changes of Tuberoinfundibular Dopaminergic Neuron Activity in the Rat: Role of Cholinergic Control. <i>Biol Reprod</i> . 1996 May;54(5):987-92.	
/S.J./	C43	SHYTLE et al., Transdermal Nicotine for Tourette's Syndrome. <i>Drug Dev. Res</i> . 1996; 38:290-98.	
/S.J./	C44	SHYTLE et al., Researchers Exploring Nicotine as a TS Treatment. <i>Tourette Syndrome Ass., Inc</i> . 1997; 25(1, 3, 7).	
/S.J./	C45	SILVER et al., Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. <i>J Am Acad Child Adolesc Psychiatry</i> . 1996 Dec;35(12):1631-6.	
/S.J./	C46	SANDBERG et al., Nicotine gum and haloperidol in Tourette's syndrome. <i>Lancet</i> . 1988 Mar 12;1(8585):592.	
/S.J./	C47	SANDBERG et al., Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome. <i>Lancet</i> . 1993 Jul 17;342(8864):182.	
/S.J./	C48	SOLOMONS, Organic Chemistry. 1984 3 <sup>rd</sup> ed.: 419.	
/S.J./	C49	SHYTLE et al., Nicotine, tobacco and addiction. <i>Nature</i> . 1996 Nov 7;384(6604):18-9.	
/S.J./	C50	(No authors listed) Mecamylamine. The Merck Index, 11 <sup>th</sup> edition, Budavari et al. Merck & CO., Inc. 1989:5657.	

EXAMINER: /Samira Jean-louis/	DATE CONSIDERED: 03/14/2009
----------------------------------	--------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./